Now showing items 1-4 of 4

    • In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems 

      Semete, Boitumelo; Booysen, Laetitia; Lemmer, Yolandy; Kalombo, Lonji; Katata, Lebogang; Verschoor, Jan (Elsevier Inc., 2010-10)
      The remarkable physicochemical properties of particles in the nanometer range have been proven to address many challenges in the field of science. However, the possible toxic effects of these particles have raised some ...
    • Mycolic acids, a promising mycobacterial ligand for targeting of nanoencapsulated drugs in tuberculosis 

      Lemmer, Yolandy; Kalombo, Lonji; Pietersen, Ray-Dean; Jones, Arwyn T.; Semete-Makokotlela, Boitumelo; Van Wyngaardt, Sandra; Ramalapa, Bathabile; Stoltz, Anton C.; Baker, Bienyameen; Verschoor, Jan A.; Swai, Hulda; de Chastellier, Chantal (Elsevier, 2015-06-06)
      The appearance of drug-resistant strains of Mycobacterium tuberculosis (Mtb) poses a great challenge to the development of novel treatment programmes to combat tuberculosis. Since innovative nanotechnologiesmight ...
    • Spray-Dried, Nanoencapsulated, Multi-Drug Anti-Tuberculosis Therapy Aimed at OnceWeekly Administration for the Duration of Treatment 

      Kalombo, Lonji; Lemmer, Yolandy; Semete-Makokotlela, Boitumelo; Ramalapa, Bathabile; Nkuna, Patric; Booysen, Laetitia; Naidoo, Saloshnee; Hayeshi, Rose; Verschoor, Jan; Swai, Hulda (MDPI, 2019-08-15)
      Aiming to improve the treatment outcomes of current daily tuberculosis (TB) chemotherapy over several months, we investigated whether nanoencapsulation of existing drugs would allow decreasing the treatment frequency to ...
    • State of the art and future directions in nanomedicine for tuberculosis. 

      Dube, Admire; Lemmer, Yolandy; Hayeshi, Rose; Balogun, Mohammed; Labuschagne, Philip; Swai, Hulda; Kalombo, Lonji (Expert Opinion on Drug Delivery, 2013-12-01)
      Introduction: Tuberculosis (TB) ranks the second leading cause of death from an infectious disease worldwide. However, treatment of TB is affected by poor patient compliance due to the requirement for daily drug administration, ...